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Cardiovascular diseases (CVD) are the major cause of
mortality and morbidity worldwide, despite significant ad-
vances in our understanding of the underlying atheroscle-
rotic process, its prevention and its treatment. Simple,
accessible and cost-effective preventive therapies aimed at
reducing the burden of CVD could be of great public health
benefit. Therefore, substantial interest has focused on the
potential benefits of antioxidant vitamins in cardiovascular
prevention.
The potential role of antioxidant vitamins in CVD
prevention is based on the biological rationale rendered by
the “oxidative modification hypothesis,” which proposes an
essential role for the oxidation of lipoproteins in the genesis
and progression of atherosclerotic lesions, and by observa-
tional epidemiologic studies, that have shown associations
between the dietary and supplemental intake of antioxidants
and lower risk of coronary heart disease (CHD) and stroke.
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The hypothesis that oxidative modification of lipopro-
teins, particularly of low density lipoprotein (LDL) choles-
terol, may play an important causative role in atherosclerosis
was advanced by Steinberg et al. (1) and is supported by an
impressive body of in vitro findings and by rather persuasive
findings in animal models of atherosclerosis. It was sug-
gested that oxidation of LDL was particularly involved in
the formation of foam cells and thus in the genesis of early
atherosclerotic lesions. The relevance of LDL oxidation in
human atherosclerosis, although widely accepted, has not
been, however, conclusively proven, as there is no clinical
evidence to date to clearly demonstrate that antioxidants can
affect either the behavior of atherosclerotic lesions or pre-
vent ischemic events.
A large number of observational epidemiologic studies
have evaluated potential relationships between antioxidants
and CVD. Such studies range from retrospective observa-
tions to broad cross-sectional geographic correlations be-
tween population-based antioxidant intake and rates of
CHD, to large prospective cohort studies conducted in
different parts of the world, characterized by a variety of
dietary patterns and involving tens of thousands of men and
women followed for prolonged periods of time. These
studies suggested that: 1) persons with a high intake of fruits
and vegetables have a lower incidence of ischemic heart
disease events and strokes compared with those with low
intake of these nutrients (2,3); and 2) increased intake of
antioxidants through diet or supplements, particularly vita-
mins E (alpha-tocopherol) and C and beta-carotene, is
associated with a lower risk of CHD and death (4).
Although the data on “healthy” diets that contain large
amounts of fruits and vegetables are generally consistent, it
is obviously very difficult to isolate which components of
such diets indeed account for protection against atheroscle-
rotic diseases.
The observational data on specific antioxidants and car-
diovascular risk are, however, less consistent. For example,
inverse associations between dietary or supplemental intake
of beta-carotene and the risk of fatal and nonfatal CHD
were shown primarily in men (5,6), whereas the larger
studies in women documented neutral effects (7,8). Vitamin
C appeared to be cardioprotective on crude analysis in some
studies (7), but after adjustment for vitamin E intake this
association lost statistical significance in most investiga-
tions; overall, seven studies done in the U.S. and in Europe,
involving a total of 183,662 men and women ages 16 to 105
years, failed to show lower CVD rates with vitamin C, after
adjustment for different variables including vitamin E intake
(9). The epidemiologic data on vitamin E and reduced
cardiovascular risk is more robust, although some questions
remain. Thus, the Nurses’ Health Study and the Health
Professionals Follow-up Study clearly identify the use of
vitamin E in the form of supplements—that is, in higher
doses than generally provided by balanced diets—to be
beneficial and suggested that the observed benefit was
associated only with relatively high intake of vitamin E
supplements of at least 100 IU/day (5,7). By contradistinc-
tion, a large epidemiologic study in postmenopausal women
conducted in the U.S. and a large cohort study from Finland
identified vitamin E from food sources to be potentially
cardioprotective, with no benefits from vitamin E in the
form of supplements in the North American study (8,10).
Furthermore, the interpretation of any observational data
needs to be very cautious, recognizing that such studies
cannot provide proof of causality. Although many observa-
tional studies have attempted to adjust for other factors that
could affect cardiovascular risk, such adjustments are diffi-
cult and often inadequate, and ultimately the use of diets
rich in antioxidants and/or the use of vitamin supplements
may be just markers that identify populations and subsets of
individuals with higher health awareness and with various
healthy lifestyle attributes, possibly entirely independent of
antioxidant intake.
Randomized prospective morbidity and mortality trials
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are therefore considered to be quintessential in demonstrat-
ing the efficacy and the safety of any therapeutic interven-
tion. Such trials were deemed necessary prior to making
wide-ranging recommendations regarding the use of anti-
oxidant supplements. Unfortunately, the overwhelming ma-
jority of large, randomized and prospective trials of antiox-
idant supplements in CVD have yielded disappointing
results (9,11–16). The randomized clinical trials completed
to date have tested primarily vitamin E and beta-carotene,
with only limited data for vitamin C, and they have been
conducted in men and in women in primary and in
secondary prevention settings. The only two positive studies
have both used vitamin E supplements, one in CHD and
the other in end-stage renal-disease patients (17,18). These
studies were relatively small and found benefits on nonfatal
myocardial infarction, but not on cardiovascular death.
These large prospective, randomized clinical trials have
been, however, criticized as well. It was suggested that the
study patients comprised primarily men and women with
advanced atherosclerosis and that the failure of antioxidant
vitamins to demonstrate benefit may be related to the fact
that micronutrients and nutriceuticals could be expected to
have an effect only on the very early stages of atherosclerosis
and not on terminal events such as plaque rupture and
thrombosis. It has also been suggested that studies of four to
six years’ duration are too short to show a treatment effect,
considering again that the hypothesized benefit would be
primarily on the initiation of atherosclerotic lesions. Some
investigators have suggested that it may be more relevant to
study combinations of antioxidants, as the use of isolated
single agents may actually result in pro-oxidative actions.
Finally, it has recently been suggested that the average
Western diet may provide adequate supplies of vitamin E, at
least in a large proportion of individuals, and it may be
difficult to observe benefits in this population with addi-
tional supplemental vitamin E intake and that clinical trials,
therefore, should select subjects with vitamin-deficient
states (19).
Because of these perceived limitations of large prospective
trials with clinical end points Steinberg et al. (1) suggested
that an additional strategy to evaluate antioxidants may be
to study associations and treatment effects on atherosclerotic
lesions. A number of investigations have evaluated associa-
tions between dietary and supplemental vitamin intake and
carotid atherosclerosis, and there are also a few randomized
controlled trials of antioxidant supplementation using as
surrogates outcome changes in carotid intimal-medial
thickness (IMT). Such randomized trials have been negative
(20), with the exception of a subgroup analysis of the
Antioxidant Supplementation in Atherosclerosis Prevention
(ASAP) study, which found benefit in hypercholesterolemic
men who smoked and received combined supplementation
of vitamins E and C (21).
In this issue of the Journal, McQuillan et al. (22) report
an elegant observational study that examined relationships
between dietary intake and plasma levels of antioxidant
vitamins and carotid IMT. The study is well designed and
enrolls over 1,000 men and women from Western Australia.
Study participants have a mean age of 52 years for men and
53 years for women and an average prevalence of other risk
factors for atherosclerosis, typical for relatively healthy
individuals in Western societies. Subjects with known CVD
are appropriately excluded from the analysis, as these indi-
viduals may be more motivated to have higher antioxidant
vitamin intake.
The methodology used for the dietary assessment, the
measurements of plasma levels of different antioxidants and
the assessment of atherosclerosis are adequate. As indicated
by the investigators, such measurements of carotid arterial
wall thickness have been clearly shown to independently
predict the risk of myocardial infarction and stroke in
populations.
Unfortunately, I find the study results disappointing
overall and a bit confusing. Dietary vitamin E intake is
found to have an inverse relationship with carotid IMT in
men; however, this relationship is very weak and explains
only 1% of the variance in measured IMT in men. Further-
more, the relationship is not confirmed in women. There
would be little biological rationale to support a differential
effect of antioxidant vitamin E intake on the carotid arterial
wall in men as compared to women. No relationships are
found between dietary intake of other antioxidants such as
vitamin C, beta-carotene and other naturally derived caro-
tenoids and carotid IMT.
The large number of associations examined also raises the
question as to whether the statistically significant associa-
tion between vitamin E intake in men and carotid athero-
sclerosis may be a chance finding. The investigators (22)
found also no independent association between the intake of
vitamin supplements, including vitamin E, and carotid IMT
and between dietary intake or plasma antioxidant vitamin
levels and the risk of developing discrete carotid plaques. A
weak relationship between plasma lycopene levels and ca-
rotid IMT is reported in women although no such correla-
tion is found in men. Thus, overall, I believe that the study
by McQuillan et al. (22) provides very little support for an
association between antioxidant intake and/or plasma levels
and early carotid atherosclerosis. The investigators honestly
and appropriately outline the many neutral findings of their
study and conclude that any association between individual
antioxidant vitamins and early atherosclerosis, if present, is
likely to be modest.
Although the investigators are thoughtful and cautious, I
find their conclusion too optimistic, in that they ultimately
do suggest that the study provides limited support for the
hypothesis that dietary consumption of vitamin E may
reduce the development of early atherosclerosis. As outlined
in the Discussion section of their study, previous observa-
tional reports of subclinical atherosclerosis evaluated by
carotid IMT and antioxidant vitamins have also generally
yielded quite confusing and often conflicting results. Al-
though some differences between the results of different
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reports may be explained by differences in dietary habits of
the populations studied, there are major inconsistencies
even within individual studies. For example, a report from
the Atherosclerosis Risk In Communities (ARIC) group
found individuals with the highest carotid IMT to
have lower levels of plasma carotenoids but higher alpha-
tocopherol and retinol levels compared to controls (23).
Thus, the current study (22) and the previous observa-
tional evaluations of carotid atherosclerosis and antioxidants
fail in general to fulfill the expectation, that use of this
technique, which allows the identification of early athero-
sclerosis, may lead to a more consistent demonstration of a
relationship between dietary antioxidants and atheroscle-
rotic disease.
Similar to many previous studies, the current report
by McQuillan et al. (22) demonstrates again that our
ability to evaluate micronutrients from dietary question-
naires is modest at best. Though plasma antioxidant
levels did correlate with dietary intake assessments, these
correlations were relatively weak. This observation com-
bined with similar results from a multitude of other studies
points out significant limitations of our current tools to
assess dietary intake of micronutrients and may therefore
explain some of the confusing results when using such tools
in the study of associations between micronutrients and
cardiovascular risk.
To date we do not have clear evidence that antioxidants
provided by dietary intake or the addition of antioxidants in the
form of vitamin supplements can reduce the risk of atheroscle-
rosis. A number of studies are currently ongoing and will
evaluate combinations of antioxidants and longer-term use in
different populations, including those more susceptible to have
early vascular damage. This research is necessary and should be
encouraged. Until clear results emerge, however, neither indi-
vidual persons nor physicians should focus their efforts in
preventing heart disease and stroke on intake of such vitamin
supplements or other alternative medicines. Prevention has
been clearly and conclusively demonstrated to be the most
efficacious strategy in fighting atherosclerotic diseases. Effective
interventions are available and include smoking cessation,
exercise, cholesterol lowering, blood pressure lowering and in
high-risk individuals with established CVD the use of phar-
macologic interventions such as aspirin, statins, beta-blockers
and angiotensin-converting enzyme inhibitors. Clear and ra-
tional guidelines for the management of the major cardiovas-
cular risk factors have been outlined, and there is an urgent
need to find more effective strategies to fight obesity, physical
inactivity, smoking and diabetes.
We need to focus on the use of such preventive strategies
with proven efficacy. Their implementation requires effort,
patience and perseverance. The hope that other alternative
interventions may be useful can detract from the focus
required to implement these proven preventive strategies.
Whereas further research is mandatory and should be
encouraged, until we do have conclusive proof that other
preventive measures, such as antioxidant vitamins, are ben-
eficial, these should not be part of our main therapeutic
regimen in CVD prevention.
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